Details
Stereochemistry | ACHIRAL |
Molecular Formula | CHO3.Na |
Molecular Weight | 84.0066 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC([O-])=O
InChI
InChIKey=UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
DescriptionSources: https://www.drugs.com/dosage/sodium-bicarbonate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/10932544Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26617001 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/16864561
Sources: https://www.drugs.com/dosage/sodium-bicarbonate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/10932544
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26617001 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/16864561
Diammonium carbonate is a salt with the chemical formula (NH4)2CO3. Since it readily degrades to gaseous ammonia and carbon dioxide upon heating, it is used as a leavening agent and also as smelling salt. Ammonium carbonate may be used as a leavening agent in traditional recipes, particularly those from northern Europe and Scandinavia (e.g. Speculoos, Tunnbröd or Lebkuchen). It also serves as an acidity regulator and has the E number E503. Ammonium carbonate is the main component of smelling salts, although the commercial scale of their production is small. Buckley's cough syrup from Canada today uses ammonium carbonate as an active ingredient intended to help relieve symptoms of bronchitis. Ammonium carbonate is also used as an emetic.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23078755 |
85.0 mM [Ki] | ||
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15357993 |
12.0 mM [Ki] | ||
Target ID: CHEMBL4789 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15664814 |
95.0 mM [Ki] | ||
Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16621537 |
0.27 mM [Ki] | ||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15664814 |
0.086 mM [Ki] | ||
Target ID: CHEMBL3025 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21208801 |
0.8 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
|||
Curative | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
|||
Primary | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
Sample Use Guides
In cardiac arrest, a rapid intravenous dose of one to two 50 mL syringes (44.6 to 100 mEq) may be given initially and continued at a rate of 50 mL (44.6 to 50 mEq) every 5 to 10 minutes if necessary (as indicated by arterial pH and blood gas monitoring) to reverse the acidosis. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia.
In less urgent forms of metabolic acidosis. Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-to- eight-hour period is approximately 2 to 5 mEq/kg of body weight - depending upon the severity of the acidosis as judged by the lowering of total CO2 content blood pH and clinical condition of the patient In metabolic acidosis associated with shock, therapy should be monitored by measuring blood gases, plasma osmolar'rty, arterial blood lactate, hemodynamics and cardiac rhythm. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid- base status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27762345
A. thaliana var. Landsberg erecta (LER) suspension cells were treated with NaHCO3 at a final concentration of 1, 3, or 10 mM. For controls, NaNO3 (NO3 − is a macronutrient in MS media) was added in same concentration to nullify the effect of Na+ during the treatment. Furthermore, as HCO3 − induced significant pH changes of the MS media (pH 5.8), we added 50 mM (for 1 mM and 3 mM HCO3 −) and 100 mM (for 10 mM HCO3 −) MES buffer (pH 5.8) to the MS media, and the pH-stabilized MS media were used for both control and HCO3− treatments. In addition, the buffered MS media were sonicated to remove atmospheric gases prior to addition of HCO3−. Cells were incubated at 25 °C for 0, 5, 15, 30, 60, and 120 min on a shaker, and four replicates (n = 4) were generated for each data point after treatment with HCO3 − (treatment) and control. After treatment, 100 ml cells at a concentration of 3 x 10^6 ml−1 were filtered using filter paper mounted on funnels, quickly blotted dry using Kim wipes and immediately snap-frozen in liquid nitrogen and stored in a − 80 °C freezer until metabolite extraction.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
219 (Number of products:117)
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-VATC |
QG04BQ01
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
NCI_THESAURUS |
C29730
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-500(II)
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
JECFA EVALUATION |
INS-500(II)
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
403513
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
CFR |
21 CFR 184.1736
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-VATC |
QB05CB04
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
EPA PESTICIDE CODE |
73505
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
26.2
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-ATC |
B05XA02
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
CFR |
21 CFR 347.10
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-VATC |
QB05XA02
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
WHO-ATC |
B05CB04
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
697
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
m9989
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | Merck Index | ||
|
134031
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
SUB12290MIG
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
SODIUM BICARBONATE
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL1353
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
C29457
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
516892
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
4507
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
144-55-8
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
1613655
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
205-633-8
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
4205
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
36676
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID9021269
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
D017693
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
8MDF5V39QO
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
8MDF5V39QO
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
32139
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
DB01390
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
100000079337
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | |||
|
SODIUM BICARBONATE
Created by
admin on Fri Dec 15 16:35:34 GMT 2023 , Edited by admin on Fri Dec 15 16:35:34 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Soluble in water; practically insoluble in ethanol (~750 g/l) TS. Category: Systemic alkalinizing agent; antacid. Storage: Sodium hydrogen carbonate should be kept in well-closed containers.Additional information. Sodium hydrogen carbonate has a saline and slightly alkaline taste. It is stable in air, but slowly decomposes in moist air. Definition: Sodium hydrogen carbonate contains not less than 99.0% and not more than 101.0% of NaHCO3, calculated with reference to the dried substance. |
ACTIVE MOIETY
SUBSTANCE RECORD